PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis PeptiDream Inc., a public Kanagawa, ...
Janssen Pharmaceutica NV has identified interleukin-17A (IL-17A)/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results